Abstract
Among several pharmacological properties, analgesia is the most common feature shared by either opioid or cannabinoid systems. Cannabinoids and opioids are distinct drug classes that have been historically used separately or in combination to treat different pain states. Indeed, it is widely known that activation of either opioid or cannabinoid systems produces antinociceptive properties in different pain models. Moreover, several biochemical, molecular and pharmacological studies support the existence of reciprocal interactions between both systems, suggesting a common underlying mechanism. Further studies have demonstrated that the endogenous opioid system could be involved in cannabinoid antinociception and recent data have also provided evidence for a role of the endogenous cannabinoid system in opioid antinociception. These interactions may lead to additive or even synergistic antinociceptive effects, emphasizing their clinical relevance in humans in order to enhance analgesic effects with lower doses and consequently fewer undesirable side effects. Thus, the present review is focused on bidirectional interactions between opioids and cannabinoids and their potent repercussions on pain modulation.
Keywords: Opioids, Cannabinoids, Antinociception, Bidirectional interactions, Synergism, Clinical implications
Current Drug Targets
Title: Opioids and Cannabinoids Interactions: Involvement in Pain Management
Volume: 11 Issue: 4
Author(s): Julie Desroches and Pierre Beaulieu
Affiliation:
Keywords: Opioids, Cannabinoids, Antinociception, Bidirectional interactions, Synergism, Clinical implications
Abstract: Among several pharmacological properties, analgesia is the most common feature shared by either opioid or cannabinoid systems. Cannabinoids and opioids are distinct drug classes that have been historically used separately or in combination to treat different pain states. Indeed, it is widely known that activation of either opioid or cannabinoid systems produces antinociceptive properties in different pain models. Moreover, several biochemical, molecular and pharmacological studies support the existence of reciprocal interactions between both systems, suggesting a common underlying mechanism. Further studies have demonstrated that the endogenous opioid system could be involved in cannabinoid antinociception and recent data have also provided evidence for a role of the endogenous cannabinoid system in opioid antinociception. These interactions may lead to additive or even synergistic antinociceptive effects, emphasizing their clinical relevance in humans in order to enhance analgesic effects with lower doses and consequently fewer undesirable side effects. Thus, the present review is focused on bidirectional interactions between opioids and cannabinoids and their potent repercussions on pain modulation.
Export Options
About this article
Cite this article as:
Desroches Julie and Beaulieu Pierre, Opioids and Cannabinoids Interactions: Involvement in Pain Management, Current Drug Targets 2010; 11 (4) . https://dx.doi.org/10.2174/138945010790980303
DOI https://dx.doi.org/10.2174/138945010790980303 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
An Introduction to the Nutrition and Metabolism of Choline
Central Nervous System Agents in Medicinal Chemistry Therapeutic Targeting of CD6 in Autoimmune Diseases: A Review of Cuban Clinical Studies with the Antibodies IOR-T1 and Itolizumab
Current Drug Targets Evaluation of Pharmacological Treatment Strategies in Traumatic Brain Injury
Current Pharmaceutical Design Potential Deployment of Angiotensin I Converting Enzyme Inhibitors and of Angiotensin II Type 1 and Type 2 Receptor Blockers in Cancer Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Adenosine and ATP Receptors in the Brain
Current Topics in Medicinal Chemistry CGRP-Receptor Antagonism in Migraine Treatment
CNS & Neurological Disorders - Drug Targets Nocturia in Obstructive Sleep Apnea-Hypopnea Syndrome: An Underappreciated Symptom
Current Respiratory Medicine Reviews What have Genetically Engineered Mice Taught Us About Ischemic Injury?
Current Molecular Medicine The 5-HT1B Receptor: A Novel Target for the Pathophysiology of Depression
Current Drug Targets Antihypertensive Effect of Sesamin
Vascular Disease Prevention (Discontinued) Discovery and Development of Antifungal Compounds
Current Medicinal Chemistry - Anti-Infective Agents Prodrugs in Photodynamic Anticancer Therapy
Current Pharmaceutical Design COVID-19 Severity: Lung-Heart Interplay
Current Cardiology Reviews Vasopressin Receptor Antagonists in Heart Failure
Recent Patents on Cardiovascular Drug Discovery Bacterial Toxins: Potential Weapons Against HIV Infection
Current Pharmaceutical Design Phospholipase A2 Myotoxins from Bothrops Snake Venoms: Structure- Function Relationship
Current Organic Chemistry The Clinical Problems of Hypertension Treatment in Hemodialysis Patients
Current Vascular Pharmacology Mechanisms Underlying the Hepatotoxic Effects of Ecstasy
Current Pharmaceutical Biotechnology Angiogenic Growth Factors in the Treatment of Peripheral Arterial Disease
Current Vascular Pharmacology The Clinical Pathway for Hypertensive Patient of Local Health Unit, Hospitals and General Practitioners, the Milan Experience
Reviews on Recent Clinical Trials